June 11th, 2015

Keystone Nano is pleased to announce the publication of a manuscript describing the preclinical development of the company's lead product, the Ceramide Nanoliposome (CNL). This product is designed to more effectively treat cancer by providing selectively killing cancer cells without harming normal cells.

Keystone Nano is currently compiling an Investigational New Drug filing on the Ceramide Nanoliposome for review by the US Food and Drug Administration. The company anticipates that the initial clinical trial will treat patients with a range of cancers. After this initial testing is complete, the company anticipates enrolling in clinical testing patients with Liver Cancer or other difficult to treat cancers.